

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Equality and health inequality impact assessment

STA Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma

Final draft guidance

- 1 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

It was suggested that the recommendation in the draft guidance was unfair to people that were not offered lenalidomide at first line (which may be linked to age and transplant eligibility). The recommendation in the final draft guidance no longer requires people to have had a previous line of treatment which contained lenalidomide.

- 2 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No issues were identified.

- 3 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

The changed recommendations do not make it more difficult for a specific group to access the technology than other groups.

- 4 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments in the recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE’s obligations to promote equality.**

No, the committee did not make any other reasonable adjustments in the recommendations.

- 5 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?**

The committee did not think that its recommendation would increase or reduce any health inequalities.

- 6 Have the committee’s considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

Yes, Section 3.23

Approved by senior responsible officer: Richard Diaz

Date: 17/03/2026